摘要
目的探讨肿瘤特异性黑色素瘤抗原(MAGE)-1、-3基因作为胶质瘤的免疫检测和治疗、基因治疗分子标志物的可行性。方法采用逆转录-聚合酶链反应(RT-PCR)检测52例胶质瘤、6例正常脑组织、5例脑脓肿、10例脑膜瘤组织标本中MAGE-1、MAGE-3mRNA的表达。结果脑胶质瘤中MAGE-1、MAGE-3mRNA阳性表达率分别为64.5%、55.8%,MAGE-1及MAGE-3mRNA同时表达22例(42.3%)。正常脑组织、脑脓肿和脑膜瘤均不表达MAGE-1和MAGE-3mRNA。在胶质瘤组织中MAGE-1、MAGE-3mRNA的表达均与病理级别和病人生存时间有关(P<0.05),而与性别、年龄、肿瘤部位及肿瘤直径无关(P>0.05)。MAGE-1的表达与MAGE-3的表达有关(P<0.05)。结论基于MAGE-1和MAGE-3基因在胶质瘤中的高表达率,可利用这两种蛋白作为靶分子进行免疫治疗,同时也可作为一种临床有用的随访指标。
Objective To evaluate the feasibility of MAGE-1 and MAGE-3 genes encoding proteins used as a target in immunotherapy of brain glioma. Methods Reverse transcriptase-polymerase chain reaction（RT-PCR） was used for detection of mRNA of MAGE-1 and MAGE-3 in the specimens from brain glioma （n=52）, normal brain tissue （n=6）, intracerebral abscess （n=5） and meningioma （n=10）. Results In 52 cases of brain glioma, the positive expression rate ofmRNA of MAGE-1 and MAGE-3 was 64.5% and 55.8% respectively; and simultaneous expression of both mRNA of MAGE-1 and MAGE-3 was 42.3% （22 cases）, but neither of them was expressed in normal brain tissue, intracerebral abscess and meningioma. The expression of mRNA of MAGE-1 and MAGE-3 in brain glioma was related to pathologic grades and survival time （P〈0.05）, but irrelevant to sex, age, location of tumor and diameter of tumor （P〉0.05）. The expression of MAGE-1 gene in brain glioma was related to MAGE-3 gene （P〈0.05）. Conclusion MAGE-1 and MAGE-3 proteins may be used as target molecules in the immunotherapy of glioma and on the other hand, as indexes for follow-up study of glioma.
出处
《中华神经医学杂志》
CAS
CSCD
2005年第9期908-910,共3页
Chinese Journal of Neuromedicine
